Australia's most trusted
source of pharma news
Monday, 02 February 2026
Posted 29 January 2026 AM
After a hitting a dead end for reimbursement on the PBS for breast cancer drug Nerlynx, there's been a win for local company Specialised Therapeutics (ST) which has launched the therapy in Thailand.
Under exclusive license from Puma Biotech, Nerlynx is considered an important new treatment option for women with HER2+ breast cancer, shown to significantly reduce the risk of cancer recurrence and improve disease-free survival.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.